Article Information
- Received August 9, 2022
- Revision received December 9, 2022
- Accepted December 15, 2022
- First published January 3, 2023.
- Version of record published February 8, 2023.
Author Information
Author contributions
Author contributions: E.M.-L., D.J.V., T.L., S.J.M., S.S.C., and C.A.G. designed research; E.M.-L., D.J.V., T.L., S.J.M., L.E.H., R.M.H., N.S., B.B., K.H., and B.Y. performed research; E.M.-L., D.J.V., T.L., S.J.M., L.E.H., R.M.H., B.Y., S.S.C., and C.A.G. analyzed data; E.M.-L. wrote the first draft of the paper; E.M.-L., D.J.V., L.E.H., B.Y., S.S.C., and C.A.G. edited the paper; E.M.-L., D.J.V., S.S.C., and C.A.G. wrote the paper.
Disclosures
- Received August 9, 2022.
- Revision received December 9, 2022.
- Accepted December 15, 2022.
This work was funded by the Department of Defense Grants 81XWH-17-1-0564 (to S.S.C. and C.A.G.) and W81XWH1910264 (to V.D.J.), the National Institutes of Health (NIH) Grant 1RF1NS110354-01, the Parkinson's Foundation Research Center of Excellence Grant PF-RCE-1946 (to S.S.C.), and NIH Grants DC016851, DC017989, and DC013791 (to C.A.G.). The Yale/National Institute on Drug Abuse (NIDA) Neuroproteomic Center is supported by grant 5P30DA018343-18. We thank Christine Kaliszewski for technical assistance with EM and John E. Lee for a-syn-Tg and WT animal colonies maintenance and genotyping. We also thank Tukiet Lam and Yale/NIDA Neuroproteomic Center for the mass spectrometry (S10OD018034) and Phil Coish for reading the manuscript.
The authors declare no competing financial interests.
- Correspondence should be addressed to Charles A. Greer at charles.greer{at}yale.edu or Sreeganga S. Chandra at sreeganga.chandra{at}yale.edu
Funding
U.S. Department of Defense (DOD)
W81XWH1710564; W81XWH1910264Parkinson's Foundation Research 516 Center of Excellence
PF-RCE-1946HHS | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD)
DC016851-06A1; DC017989-03; DC013791-03HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
1RF1NS110354-01HHS | NIH | NIDA | National Drug Abuse Treatment Clinical Trials Network (CTN)
5P30DA018343-18
Other Version
- previous version (January 03, 2023).
- You are viewing the most recent version of this article.
Online Impact
